Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities.

Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J, Struble K, Watts H, Flexner C.

Lancet HIV. 2019 Aug;6(8):e552-e558. doi: 10.1016/S2352-3018(19)30147-X. Epub 2019 Jul 12. Review.

PMID:
31307946
2.

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.

Lommerse J, Clarke D, Kerbusch T, Merdjan H, Witjes H, Teppler H, Mirochnick M, Acosta EP, Wenning L, Nachman S, Chain A.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 18. doi: 10.1002/psp4.12443. [Epub ahead of print]

3.

Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161).

Neilan AM, Patel K, Agwu AL, Bassett IV, Amico KR, Crespi CM, Gaur AH, Horvath KJ, Powers KA, Rendina HJ, Hightow-Weidman LB, Li X, Naar S, Nachman S, Parsons JT, Simpson KN, Stanton BF, Freedberg KA, Bangs AC, Hudgens MG, Ciaranello AL.

JMIR Res Protoc. 2019 Apr 16;8(4):e9898. doi: 10.2196/resprot.9898.

4.

Profiles of caregiving behaviors among children and adolescents with perinatally acquired HIV.

Rabinowitz JA, Osigwe I, Godshalk L, Drabick DAG, Nachman S, Gadow KD.

AIDS Care. 2019 Jun;31(6):737-745. doi: 10.1080/09540121.2019.1576850. Epub 2019 Feb 7.

PMID:
30732458
5.

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

Nachman S, Alvero C, Teppler H, Homony B, Rodgers AJ, Graham BL, Fenton T, Frenkel LM, Browning RS, Hazra R, Wiznia AA; IMPAACT 1066 study team.

Lancet HIV. 2018 Dec;5(12):e715-e722. doi: 10.1016/S2352-3018(18)30257-1.

6.

Tuberculosis preventive treatment preferences among care givers of children in Lesotho: a pilot study.

Hirsch-Moverman Y, Mantell JE, Lebelo L, Wynn C, Hesseling AC, Howard AA, Nachman S, Frederix K, Maama LB, El-Sadr WM.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):858-862. doi: 10.5588/ijtld.17.0809.

PMID:
29991393
7.

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.

Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, Nachman S, Smith B, Diacon AH, Hesseling AC, Garcia-Prats AJ.

Br J Clin Pharmacol. 2018 Jun 27. doi: 10.1111/bcp.13696. [Epub ahead of print]

8.

High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial.

Cranmer LM, Draper HR, Mandalakas AM, Kim S, McSherry G, Krezinski E, Coetzee J, Mitchell C, Nachman S, van der Linde M, Cotton MF, Hesseling AC; IMPAACT P1041 Team.

Pediatr Infect Dis J. 2018 Oct;37(10):e254-e256. doi: 10.1097/INF.0000000000001946.

PMID:
29462104
9.

Assessing Psychiatric Symptoms in Youth Affected by HIV: Comparing a Brief Self-Administered Rating Scale with a Structured Diagnostic Interview.

Chernoff M, Angelidou KN, Williams PL, Brouwers P, Warshaw M, Nachman S; IMPAACT P1055 Study Team.

J Clin Psychol Med Settings. 2018 Dec;25(4):420-428. doi: 10.1007/s10880-018-9550-2.

PMID:
29460107
10.

Childhood adversity increases the risk of onward transmission from perinatal HIV-infected adolescents and youth in South Africa.

Kidman R, Nachman S, Dietrich J, Liberty A, Violari A.

Child Abuse Negl. 2018 May;79:98-106. doi: 10.1016/j.chiabu.2018.01.028. Epub 2018 Feb 20.

11.

The PREVENT study to evaluate the effectiveness and acceptability of a community-based intervention to prevent childhood tuberculosis in Lesotho: study protocol for a cluster randomized controlled trial.

Hirsch-Moverman Y, Howard AA, Frederix K, Lebelo L, Hesseling A, Nachman S, Mantell JE, Lekhela T, Maama LB, El-Sadr WM.

Trials. 2017 Nov 21;18(1):552. doi: 10.1186/s13063-017-2184-0.

12.

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT; IMPAACT P1079 protocol team.

PLoS One. 2017 Oct 24;12(10):e0186589. doi: 10.1371/journal.pone.0186589. eCollection 2017.

13.

Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.

O'Gorman MA, Michaels MG, Kaplan SL, Otley A, Kociolek LK, Hoffenberg EJ, Kim KS, Nachman S, Pfefferkorn MD, Sentongo T, Sullivan JE, Sears P.

J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):210-218. doi: 10.1093/jpids/pix037.

PMID:
28575523
14.

H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment did not induce measurable antigen-driven proliferation of the HIV-1 proviral reservoir.

Wagner TA, Huang HC, Salyer CE, Richardson KM, Weinberg A, Nachman S, Frenkel LM.

AIDS Res Ther. 2017 Feb 13;14(1):7. doi: 10.1186/s12981-017-0135-1.

15.

Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.

Zeldow B, Kim S, McSherry G, Cotton MF, Jean-Philippe P, Violari A, Bobat R, Nachman S, Mofenson LM, Madhi SA, Mitchell C.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):38-45. doi: 10.5588/ijtld.16.0149.

16.

Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Tuluc F, Spitsin S, Tustin NB, Murray JB, Tustin R 3rd, Schankel LA, Wiznia A, Nachman S, Douglas SD.

AIDS Res Hum Retroviruses. 2017 Feb;33(2):133-142. doi: 10.1089/AID.2016.0108. Epub 2016 Oct 18.

17.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

18.

Understanding NIH clinical case definitions for pediatric intrathoracic TB by applying them to a clinical trial.

Beneri CA, Aaron L, Kim S, Jean-Philippe P, Madhi S, Violari A, Cotton MF, Mitchell C, Nachman S; P1041 team.

Int J Tuberc Lung Dis. 2016 Jan;20(1):93-100. doi: 10.5588/ijtld.14.0848.

19.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7.

20.

Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women.

Weinberg A, Muresan P, Richardson K, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ; P1086 Study Team.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1170-7. doi: 10.1089/aid.2015.0151. Epub 2015 Aug 31.

21.

Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study.

Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S; International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1055 Study Team.

AIDS. 2015 Jun 19;29(10):1227-37. doi: 10.1097/QAD.0000000000000697.

22.

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.

Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C.

Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6. Review.

23.

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070. Epub 2015 Apr 28.

24.

Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine.

Weinberg A, Muresan P, Richardson KM, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ; P1086 team.

PLoS One. 2015 Apr 13;10(4):e0122431. doi: 10.1371/journal.pone.0122431. eCollection 2015.

25.

Do Patients of Subspecialist Physicians Benefit from Written Asthma Action Plans?

Sheares BJ, Mellins RB, Dimango E, Serebrisky D, Zhang Y, Bye MR, Dovey ME, Nachman S, Hutchinson V, Evans D.

Am J Respir Crit Care Med. 2015 Jun 15;191(12):1374-83. doi: 10.1164/rccm.201407-1338OC.

26.

Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth.

Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, Cunningham CK, Bloom A, Weinberg A.

PLoS One. 2015 Mar 18;10(3):e0118567. doi: 10.1371/journal.pone.0118567. eCollection 2015.

27.

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.

Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP.

J Clin Pharmacol. 2015 Jul;55(7):748-56. doi: 10.1002/jcph.493. Epub 2015 Apr 13.

28.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

29.

The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.

Naranbhai V, Kim S, Fletcher H, Cotton MF, Violari A, Mitchell C, Nachman S, McSherry G, McShane H, Hill AV, Madhi SA.

BMC Med. 2014 Jul 17;12:120. doi: 10.1186/s12916-014-0120-7.

30.

Executive summary: 2013 update of the guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children.

Siberry GK, Abzug MJ, Nachman S; Panel on Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children.

Pediatr Infect Dis J. 2013 Dec;32(12):1303-7. doi: 10.1097/INF.0000000000000080. No abstract available.

31.

Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics.

Pediatr Infect Dis J. 2013 Nov;32 Suppl 2:i-KK4. doi: 10.1097/01.inf.0000437856.09540.11. No abstract available.

32.

Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

Pass RF, Nachman S, Flynn PM, Muresan P, Fenton T, Cunningham CK, Borkowsky W, McAuley JB, Spector SA, Petzold E, Levy W, Siberry GK, Handelsman E, Utech LJ, Weinberg A; IMPAACT 1089 Team.

J Pediatric Infect Dis Soc. 2013 Dec;2(4):352-60. doi: 10.1093/jpids/pit040. Epub 2013 Jul 17.

33.

Executive Summary: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations From the National Institutes of Health, the Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Siberry GK, Abzug MJ, Nachman S; Panel on Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children—a working group of the Office of AIDS Research (OAR) Advisory Council*.

J Pediatric Infect Dis Soc. 2013 Dec;2(4):293-308. doi: 10.1093/jpids/pit074. Epub 2013 Nov 27. Review.

34.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.

Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21.

35.

Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams.

Vaccine. 2013 Oct 1;31(42):4782-90. doi: 10.1016/j.vaccine.2013.08.002. Epub 2013 Aug 14.

36.

Participation and retention of youth with perinatal HIV infection in mental health research studies: the IMPAACT P1055 psychiatric comorbidity study.

Williams PL, Chernoff M, Angelidou K, Brouwers P, Kacanek D, Deygoo NS, Nachman S, Gadow KD; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group P1055 Study Team.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):401-9. doi: 10.1097/QAI.0b013e318293ad53.

37.

Requirements for the clinical evaluation of new anti-tuberculosis agents in children.

Donald PR, Ahmed A, Burman WJ, Cotton MF, Graham SM, Mendel C, McIlleron H, Mac Kenzie WR, Nachman S, Schaaf HS, Starke JR, Wingfield C, Hesseling AC.

Int J Tuberc Lung Dis. 2013 Jun;17(6):794-9. doi: 10.5588/ijtld.12.0567.

PMID:
23676164
38.

Central Nervous System Vasculopathy in HIV-Infected Children Enrolled in the Pediatric AIDS Clinical Trials Group 219/219C Study.

Schieffelin JS, Williams PL, Djokic D, Anderson JP, Nachman S, Oleske JM, Seage GR 3rd, Van Dyke RB.

J Pediatric Infect Dis Soc. 2013 Mar;2(1):50-6. doi: 10.1093/jpids/pis095. Epub 2012 Oct 26.

PMID:
26619442
39.

Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.

Abzug MJ, Nachman SA, Muresan P, Handelsman E, Watts DH, Fenton T, Heckman B, Petzold E, Weinberg A, Levin MJ; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1086 Protocol Team.

Clin Infect Dis. 2013 May;56(10):1488-97. doi: 10.1093/cid/cit057. Epub 2013 Feb 1.

40.

High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088).

Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham CK, Spector SA, Nachman S, Siberry GK, Handelsman E, Flynn PM; IMPAACT P1088 study team.

Hum Vaccin Immunother. 2013 May;9(5):957-68. doi: 10.4161/hv.23774. Epub 2013 Jan 31.

41.

Reply to Holm et al.

Graham SM, Casenghi M, Jean-Philippe P, Hatherill M, Hesseling AC, Nachman S, Starke JR, Swaminathan S, Cuevas LE.

J Infect Dis. 2013 Mar 1;207(5):871-2. doi: 10.1093/infdis/jis769. Epub 2012 Dec 13. No abstract available.

PMID:
23242541
42.

Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South Africa.

Beneri CA, Zeldow B, Nachman S, Van der Linde M, Pillay E, Dittmer S, Kim S, Jean-Philippe P, Coetzee J, Bobat R, Hawkins E, Violari A; P1041 Team.

Int J Tuberc Lung Dis. 2013 Jan;17(1):32-8. doi: 10.5588/ijtld.12.0282.

43.

Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.

Syed SS, Balluz RS, Kabagambe EK, Meyer WA 3rd, Lukas S, Wilson CM, Kapogiannis BG, Nachman SA, Sleasman JW.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):493-500. doi: 10.1089/AID.2012.0086. Epub 2012 Dec 3.

44.

Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons.

Gadow KD, Angelidou K, Chernoff M, Williams PL, Heston J, Hodge J, Nachman S.

J Dev Behav Pediatr. 2012 Jul;33(6):456-68. doi: 10.1097/DBP.0b013e31825b8482.

45.

Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.

Abzug MJ, Qin M, Levin MJ, Fenton T, Beeler JA, Bellini WJ, Audet S, Sowers SB, Borkowsky W, Nachman SA, Pelton SI, Rosenblatt HM; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams.

J Infect Dis. 2012 Aug 15;206(4):512-22. doi: 10.1093/infdis/jis386. Epub 2012 Jun 12.

46.

Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, Siberry GK; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team.

J Pediatr. 2012 Oct;161(4):676-81.e2. doi: 10.1016/j.jpeds.2012.04.005. Epub 2012 May 22.

47.

Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, Siberry GK, Ebiasah R, Miller J, Handelsman E, Weinberg A; IMPAACT P1088 Team.

J Infect Dis. 2012 Aug 1;206(3):421-30. doi: 10.1093/infdis/jis360. Epub 2012 May 21. Erratum in: J Infect Dis. 2012 Dec 15;206(12):1951.

48.

Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.

Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Hatherill M, Hesseling AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, Madhi S, Makhene M, Marais BJ, McNeeley DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C.

J Infect Dis. 2012 May 15;205 Suppl 2:S199-208. doi: 10.1093/infdis/jis008. Epub 2012 Mar 22.

49.

Nevirapine-based therapy after suppression: can we switch?

Nachman S, McIntyre J.

Lancet Infect Dis. 2012 Jul;12(7):498-9. doi: 10.1016/S1473-3099(12)70061-0. Epub 2012 Mar 16. No abstract available.

PMID:
22424721
50.

Human immunodeficiency virus disease severity, psychiatric symptoms, and functional outcomes in perinatally infected youth.

Nachman S, Chernoff M, Williams P, Hodge J, Heston J, Gadow KD.

Arch Pediatr Adolesc Med. 2012 Jun 1;166(6):528-35. doi: 10.1001/archpediatrics.2011.1785.

Supplemental Content

Loading ...
Support Center